The UK's Medicines and Healthcare products Regulatory Agency has launched its 2030 strategy to modernise regulation of AI-enabled healthcare, medical devices and personalised medicines.

The UK government has accepted all 44 recommendations from the National Commission into the Regulation of AI in Healthcare, moving its proposed framework into implementation.

The FDA has approved new patient-facing CardioMEMS HF System capabilities that allow people with heart failure to view pulmonary artery pressure readings and receive personalised treatment updates.

Flow Neuroscience has launched FL-100 in the United States, bringing an FDA-approved at-home transcranial direct-current stimulation treatment to adults with moderate-to-severe major depressive disorder.

A UK national commission has proposed a new regulatory framework for artificial intelligence in healthcare designed to support faster adoption while maintaining safety, accountability and public trust.

The acquisition combines Cureety's therapy-specific oncology monitoring platform with Reimagine Care's AI-enabled virtual cancer-care capabilities.

Qualcomm and ASUS have launched an on-premises AI assistant programme for community pharmacies across southern Taiwan.

The acquisition moves Switchboard beyond specialty-care navigation into direct care delivery by integrating Livara’s virtual-first, value-based MSK model, alongside more than $5 million in new financing.

Acquisition adds FDA-authorised fibromyalgia therapy and strengthens smartphone-based digital health offering